Navigation Links
FDA Accepts Investigational New Drug (IND) Application for Tigris Pharmaceutical's GGTI-2418
Date:3/4/2009

BONITA SPRINGS, Fla., March 4 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, today announced that its Investigational New Drug (IND) application for the Company's geranylgeranyltransferase inhibitor (GGTI-2418) has been accepted by the U.S. Food and Drug Administration. This will allow the company to open a Phase I study evaluating the safety of GGTI-2418 during the first quarter of 2009. GGTI-2418 is a synthetic peptidomimetic inhibitor of geranylgeranyltransferase I (GGTase I) that induces apoptosis by downregulating several pivotal oncogenic and tumor survival pathways.

"We are excited to reach this important corporate milestone and to advance this novel, targeted compound into the clinic," stated Edmundo Muniz, M.D., Ph.D., President and Chief Executive Officer of Tigris. "We look forward to completing the Phase I study of GGTI-2418 in two top Phase I cancer research centers and to continuing our rapid development of this first-in-class agent. This is the first geranylgeranyltransferase inhibitor to move to clinical phase studies."

Tigris in-licensed the exclusive worldwide rights to GGTI-2418 from Yale University and the University of South Florida.

About GGTI-2418

GGTI-2418 is a synthetic peptidomimetic inhibitor of GGTase I that appears to induce apoptosis by downregulating several pivotal oncogenic and tumor survival pathways. GGTase I catalyzes the lipid posttranslational modification which is required for the function of Rho GTPases (frequently found aberrantly activated in human cancer). GGTase I inhibitors block Rho function in cancer cells and induce a G1 phase cell cycle arrest by a mechanism involving induction of the CDK inhibitors p21waf and p27kip, CDK2 and CDK4 inhibition and hypophoshorylation of the tumor suppressor Rb. GGTase I inhibitors also induce apoptosis by a mechanism involving downregulation o
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. FDA Accepts Amgens Submission and Files Biologics License Application for Denosumab
2. FDA Accepts Cell Therapeutics Zevalin sBLA and Grants Priority Review
3. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
4. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
5. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
6. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
7. FDA Accepts Immucors Response to Warning Letter
8. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
9. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
10. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
11. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 Histogen, Inc., a regenerative medicine ... grown under simulated embryonic conditions, today announced that they ... Medical, Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary ... agreement is an amendment to the existing license between ...
(Date:1/14/2014)... Texas , Jan. 14, 2014 The ... and research medicinal plants and therapeutic derivatives thereof ... health professionals, and researchers about the challenges of ... http://photos.prnewswire.com/prnh/20100430/DC95601LOGO ) The Society ...
(Date:1/14/2014)...  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology company ... addressing major unmet medical needs using RNA-targeted technologies, ... Allowance from the United States Patent and Trademark ... for the treatment of fibrosis. The patent covers ...
(Date:1/14/2014)... CA (PRWEB) January 14, 2014 Kerr Corporation, ... 10-minute video and additional how-to information about dual arch impressions ... Restorations with Dual Arch Impressions,” the blog entry serves up ... technique and houses a step-by-step demonstration by Dr. David Little ...
Breaking Biology Technology:Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Summary: Genmab Reports Results for the First Three Months of ... today results for the three month period ended March 31, ... revenues were DKK 167 million (approx. USD 36 million) for ... Genmab recognized,revenues of DKK 80 million (approx. USD 17 million)., ...
... Md., May 28 Novavax, Inc. (Nasdaq:,NVAX) a clinical-stage ... Chief Executive Officer, will be presenting at the,FBR Capital ... on,May 29, 2008 at The Grand Hyatt Hotel in ... company,s strategy, research and development progress. A,link to the ...
... NanoLogix, Inc. (Pink,Sheets: NNLX) a nano-biotechnology company ... personnel will showcase company technology at booth 1304 ... June 1-5 2008. The ASM,meeting is the world,s ... Dr. Sergey Gazenko and CEO Bret Barnhizer.,Exhibition information ...
Cached Biology Technology:Genmab Announces 2008 First Quarter Results 2Genmab Announces 2008 First Quarter Results 3Genmab Announces 2008 First Quarter Results 4NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update 2
(Date:7/9/2014)... but often can be defeated with antibiotics and then ... Now, scientists have built a new weapon against such pathogens ... journal ACS Applied Materials & Interfaces , their study ... them than medicine alone. , David Leong, Jianping Xie and ... undetectable in the human body or in places that antibiotics ...
(Date:7/9/2014)... China challenges the commonly held belief that birds evolved ... fly. The birdlike fossil is actually not a dinosaur, ... a tiny tree-climbing animal that could glide, say American ... Utah, and Alan Feduccia of the University of North ... Ornithology . , The fossil of the Scansoriopteryx ...
(Date:7/9/2014)... is one of the amphibians with the highest distribution ... areas of water where it comes into contact with ... Research carried out by the Spaniard Germn Orizaola from ... of these frogs have developed a defensive response to ... larger bodies if they co-exist with the crayfish. , ...
Breaking Biology News(10 mins):Researchers declassify dinosaurs as being the great-great-grandparents of birds 2Frogs have developed rapid defences against the red swamp crayfish 2Frogs have developed rapid defences against the red swamp crayfish 3
... are blunt. In an attempt to eradicate tumors, oncologists ... healthy tissue along with the cancerous growths. New research ... bring scientists closer to designing cancer therapeutics that can ... last week in Science Express, follow a ...
... Although sildenafil is best known for promoting erections, it may also ... store more healthy "brown fat" relative to unhealthy "white fat" than ... research published online in The FASEB Journal , ... has been well known as a messenger molecule used by the ...
... MD FASEB MARC (Maximizing Access to Research Careers) ... Genetics Society of America (GSA) Drosophila Research Conference in ... meant to promote the entry of students, postdoctorates and ... basic science community and to encourage the participation of ...
Cached Biology News:Mechanism of mutant histone protein in childhood brain cancer revealed 2Drug for erectile disorder show promise in the treatment of obesity 2
Recombinant Equine IL-6...
... Checker Kits provide two highly efficient methods ... time-consuming plasmid preparation. By using the large-scale ... need to do is to transfer partial ... the transformation plates into the solutions provided ...
... Butcher (1998). • The major histocompatibility complex ... the immunology area. There is great interest ... in their function as antigen-presenting molecules. Many ... prospect of tackling biochemical and genetic techniques ...
actin from rabbit muscle Cell Biology Cytoskeletal Probes Actin and Actin Probes...
Biology Products: